AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight (AMAZE 1)

July 8, 2026 updated by: Novo Nordisk A/S

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1)

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1150

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Argentina
      • Buenos Aires, Argentina, C1425AGC
        • Recruiting
        • Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
      • Córdoba, Argentina, 5000
        • Recruiting
        • Instituto de Investigaciones Clínicas Córdoba
      • Esperanza, Santa Fe, Argentina, S3080BQV
        • Recruiting
        • Sanatorio Esperanza
      • Godoy Cruz, Argentina, M5501ARP
        • Recruiting
        • CIPADI
      • San Nicolás, Argentina, B2900
        • Recruiting
        • Instituto de Investigaciones Clinicas San Nicolás
    • La Pampa Province
      • Santa Rosa, La Pampa Province, Argentina, 6300
        • Recruiting
        • Fundación CESIM
  • Australia
    • New South Wales
      • Campbelltown, New South Wales, Australia, 2560
        • Recruiting
        • Sydney Clinical Trials
      • Liverpool, New South Wales, Australia, 2170
        • Recruiting
        • Sydney Cardiometabolic Centre
      • Merewether, New South Wales, Australia, 2291
        • Recruiting
        • Hunter Diabetes Centre
    • Queensland
      • Chelmer, Queensland, Australia, 4068
        • Recruiting
        • Heart of Australia
  • Belgium
      • Brussels, Belgium, 1070
        • Recruiting
        • HUB - Hôpital Erasme
      • Edegem, Belgium, 2650
        • Recruiting
        • UZA - UZ Antwerpen - Department of Endocrinology
      • Ghent, Belgium, 9000
        • Recruiting
        • Universitair Ziekenhuis Gent
      • Leuven, Belgium, 3000
        • Recruiting
        • UZ Leuven - Endocrinology
      • Mechelen, Belgium, 2800
        • Recruiting
        • Meclinas
      • Roeselare, Belgium, 8800
        • Recruiting
        • AZ Delta - Roeselare
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2V 4J2
        • Recruiting
        • C-Health Partners
    • British Columbia
      • Surrey, British Columbia, Canada, V3Z 2N6
        • Recruiting
        • Ocean West Research Clinic
    • New Brunswick
      • Moncton, New Brunswick, Canada, E1G 1A7
        • Recruiting
        • G.A. Research Associates Ltd.
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H1V7
        • Recruiting
        • Nova Scotia Hlth Halifax
    • Ontario
      • London, Ontario, Canada, N5W 6A2
        • Recruiting
        • Milestone Research
  • Denmark
      • Gandrup, Denmark, 9362
        • Recruiting
        • Sanos Clinic - Gandrup
      • Gistrup, Denmark, 9260
        • Completed
        • Steno Diabetes Center Nordjylland
      • Hellerup, Denmark, 2900
        • Recruiting
        • Gentofte Hospital - Center for Klinisk Metabolisk Forskning
      • Hillerød, Denmark, 3400
        • Recruiting
        • Hillerød Endokrinologisk amb. H0652
      • Hvidovre, Denmark, 2650
        • Recruiting
        • Hvidovre Hospital Endokrinologisk forsknings afsnit 159
    • Region Syddanmark
      • Vejle, Region Syddanmark, Denmark, 7100
        • Recruiting
        • Sanos Clinic - Vejle
  • France
      • Paris, France, 75015
        • Recruiting
        • HOPITAL EUROPEEN GEORGES POMPIDOU_Service de nutrition et diabétologie
      • Pierre-Bénite, France, 69310
        • Recruiting
        • HCL-HOPITAL LYON SUD_Service d'Endocrinologie-Diabète-Nutrition
      • Saint-Herblain, France, 44800
        • Recruiting
        • CHU NANTES - HOPITAL NORD LAENNEC_Service d'Endocrinologie-Diabétologie-Nutrition
      • Toulouse, France, 31059
        • Recruiting
        • CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE-HOPITAL RANGUEIL-Service de diabétologie et nutrition
      • Vénissieux, France, 69200
        • Recruiting
        • CENTRE DE RECHERCHE CLINIQUE PORTES DU SUD_Service d'Endocrinologie-Diabétologie-Maladies Métaboliques
  • Germany
      • Bad Oeynhausen, Germany, 32545
        • Recruiting
        • Herz- und Diabeteszentrum NRW - Bad Oeynhausen
      • Elsterwerda, Germany, 04910
        • Recruiting
        • Zentrum für klinische Studien Südbrandenburg GmbH
      • Fulda, Germany, 36037
        • Recruiting
        • MVZ im Altstadt-Carree Fulda GmbH - Zentrum für klinische Studien
      • Magdeburg, Germany, 39120
        • Recruiting
        • SMO.MD GmbH - Zentrum für klinische Studien
      • Osnabrück, Germany, 49080
        • Recruiting
        • Institut für Diabetesforschung Osnabrück
      • Witten, Germany, 58455
        • Recruiting
        • Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann
  • United Kingdom
      • Bradford-on-Avon, United Kingdom, BA15 1DQ
        • Recruiting
        • The Health Centre
      • Cheshire, United Kingdom, CH65 4LE
        • Recruiting
        • EMS Healthcare
      • Hounslow, United Kingdom, TW4 7NJ
        • Recruiting
        • HMC Health - Heston - The Meadows Centre for Health
      • Nantwich, United Kingdom, CW5 5NX
        • Recruiting
        • Kiltearn Medical Centre
      • Plymouth, United Kingdom, PL5 3JB
        • Recruiting
        • Knowle House Surgery
      • Rotherham, United Kingdom, S65 1DA
        • Recruiting
        • Clifton Medical Centre
      • Soham, United Kingdom, CB7 5JD
        • Recruiting
        • Staploe Medical Centre
      • Wellingborough, United Kingdom, NN8 4RW
        • Recruiting
        • Albany House Medical Centre
    • Cornwall
      • Fowey, Cornwall, United Kingdom, PL23 1DT
        • Recruiting
        • Fowey River Practice
    • Dorset
      • Poole, Dorset, United Kingdom, BH16 5PW
        • Recruiting
        • The Adam Practice
    • North Yorkshire
      • Pickering, North Yorkshire, United Kingdom, YO18 8BL
        • Recruiting
        • Pickering Medical Practice
    • Surrey
      • Addlestone, Surrey, United Kingdom, KT15 2BH
        • Recruiting
        • The Crouch Oak Family Practice
  • United States
    • Florida
      • Miramar, Florida, United States, 33027
        • Recruiting
        • South Broward Research LLC
      • Orlando, Florida, United States, 32801
        • Recruiting
        • Clinical Neuroscience Solution
    • Georgia
      • Conyers, Georgia, United States, 30094
        • Recruiting
        • Hope Clin Res & Wellness
    • Illinois
      • Skokie, Illinois, United States, 60077
        • Recruiting
        • Endeavor Health
    • Indiana
      • Indianapolis, Indiana, United States, 46260
        • Recruiting
        • Midwest Inst For Clin Res
    • Missouri
      • City of Saint Peters, Missouri, United States, 63303
        • Recruiting
        • StudyMetrix Research LLC
    • New York
      • New York, New York, United States, 10075
        • Recruiting
        • New York Gastroenterology Associates
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27514
        • Recruiting
        • UNC Eastowne Medical Office
      • Greensboro, North Carolina, United States, 27408
        • Recruiting
        • PharmQuest Life Sciences LLC
      • Wilmington, North Carolina, United States, 28401
        • Recruiting
        • Accellacare and KDCILM, LLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Recruiting
        • UPA Ctr Weight and Eating Dis
    • Rhode Island
      • Cumberland, Rhode Island, United States, 02864
        • Recruiting
        • Clinical Res Collaborative
    • South Carolina
      • Charleston, South Carolina, United States, 29425
        • Recruiting
        • Medical Uni of SC Charleston
      • North Charleston, South Carolina, United States, 29405
        • Recruiting
        • Coastal Carolina Research Ctr
      • Simpsonville, South Carolina, United States, 29681-1538
        • Recruiting
        • Hillcrest Clinical Research
    • Texas
      • Amarillo, Texas, United States, 79124
        • Recruiting
        • Amarillo Medical Specialists
      • Dallas, Texas, United States, 75230-6855
        • Recruiting
        • Velocity Clinical Res-Dallas
      • Forney, Texas, United States, 75126
        • Recruiting
        • Care United Research, LLC
    • Virginia
      • Arlington, Virginia, United States, 22206
        • Recruiting
        • Washington Cntr Weight Mgmt
      • Newport News, Virginia, United States, 23606
        • Recruiting
        • Health Res of Hampton Roads
      • Winchester, Virginia, United States, 22601-3834
        • Recruiting
        • Selma Medical Associates
    • Washington
      • Renton, Washington, United States, 98057
        • Recruiting
        • Rainier Clin Res Ctr Inc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Key Inclusion Criteria:

  • Male or female (sex at birth).
  • Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.

Key Exclusion Criteria:

  • HbA1c ≥ 6.5% (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
  • Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: NNC0487-0111
Participants will be randomized to receive 1 out of 4 different dose levels subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: NNC0487-0111
NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Placebo Comparator: Placebo
Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: Placebo (matched to NNC0487-0111)
Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Relative change in body weight
Time Frame: From baseline (week 0) to week 84
Measured as percentage of body weight.
From baseline (week 0) to week 84

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in waist circumference
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as centimetre (cm).
From baseline (week 0) to week 84 and week 136
Change in systolic blood pressure (SBP)
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as millimetre of mercury (mmHg).
From baseline (week 0) to week 84 and week 136
Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) physical function score
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical function score ranges from 0-100.
From baseline (week 0) to week 84 and week 136
Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning score
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation (SD) of 10. Higher scores indicate better functional health and well-being. The physical functioning ranges from 19.0 to 57.6.
From baseline (week 0) to week 84 and week 136
Change in body weight
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as kilogram (kg).
From baseline (week 0) to week 84 and week 136
Change in body mass index (BMI)
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as kilograms per meter squared (kg/m^2).
From baseline (week 0) to week 84 and week 136
Change in IWQOL-Lite-CT physical composite score
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical composite score ranges from 0-100.
From baseline (week 0) to week 84 and week 136
Change in IWQOL-Lite-CT psychosocial composite score
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The psychosocial composite score ranges from 0-100.
From baseline (week 0) to week 84 and week 136
Change in IWQOL-Lite-CT total score
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The total score ranges from 0-100.
From baseline (week 0) to week 84 and week 136
Change in glycated haemoglobin (HbA1c)
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as percentage of HbA1c.
From baseline (week 0) to week 84 and week 136
Change in fasting plasma glucose (FPG)
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as millimole per liter (mmol/L).
From baseline (week 0) to week 84 and week 136
Ratio to baseline: change in fasting insulin
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as ratio.
From baseline (week 0) to week 84 and week 136
Change in diastolic blood pressure (DBP)
Time Frame: From baseline (week 0) to week 84
Measured as mmHg.
From baseline (week 0) to week 84
Ratio to baseline: change in total cholesterol
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as ratio.
From baseline (week 0) to week 84 and week 136
Ratio to baseline: change in high-density lipoprotein (HDL) cholesterol
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as ratio.
From baseline (week 0) to week 84 and week 136
Ratio to baseline: change in low-density lipoprotein (LDL) cholesterol
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as ratio.
From baseline (week 0) to week 84 and week 136
Ratio to baseline: change in very low-density lipoprotein (VLDL) cholesterol
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as ratio.
From baseline (week 0) to week 84 and week 136
Ratio to baseline: change in non-HDL cholesterol
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as ratio.
From baseline (week 0) to week 84 and week 136
Ratio to baseline: change in triglycerides
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as ratio.
From baseline (week 0) to week 84 and week 136
Ratio to baseline: change in high-sensitivity C-reactive protein (hsCRP)
Time Frame: From baseline (week 0) to week 84 and week 136
Measured as ratio.
From baseline (week 0) to week 84 and week 136
Number of treatment emergent adverse events (TEAEs)
Time Frame: From baseline (week 0) to week 84 and week 140
Measured as events.
From baseline (week 0) to week 84 and week 140
Number of treatment emergent serious adverse events (TESAEs)
Time Frame: From baseline (week 0) to week 84 and week 140
Measured as events.
From baseline (week 0) to week 84 and week 140
Number of TEAEs leading to permanent treatment discontinuation
Time Frame: From baseline (week 0) to week 84 and week 140
Measured as events.
From baseline (week 0) to week 84 and week 140
Relative change in body weight
Time Frame: From baseline (week 0) to week 136
Measured as % of body weight.
From baseline (week 0) to week 136

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Novo Nordisk A/S

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 24, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 26, 2029

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 21, 2029

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 13, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 13, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 14, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 9, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 8, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NN9490-8021
  • U1111-1313-6262 (Other Identifier: World Health Organization (WHO))
  • 2024-520440-42 (Other Identifier: European Medical Agency (EMA))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings